Pfizer’ Talzenna leads latest CHMP highlights

pharmatimes | April 29, 2019

Pfizer’ Talzenna leads latest CHMP highlights
Pfizer’s PARP inhibitor, Talzenna (talazoparib), has been given a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for adults with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, heading up April’s recommendations list. Thirteen medicines were recommended for approval at the Committee’s April 2019 meeting, including two orphan medicines; Novo Nordisk’s Esperoct (turoctocog alfa pegol), for the treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A; and Alexion’s Ultomiris (ravulizumab), for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria.

Spotlight

The first evidence of humans smoking Atropa Belladonna as a cough remedy can be dated back over 4,000 years. Fortunately, technology and expertise in inhalation drug delivery have improved significantly since then, offering better predictability, efficacy and safety of today’s widely used inhalation devices. The technology as we know it truly came into existence almost 60 years ago, when the pressurized metered dose inhaler (MDI) was invented. Today, these products are primarily used to treat COPD and asthma, but they are also suitable for many other therapeutic areas, including nasal drug delivery.

Spotlight

The first evidence of humans smoking Atropa Belladonna as a cough remedy can be dated back over 4,000 years. Fortunately, technology and expertise in inhalation drug delivery have improved significantly since then, offering better predictability, efficacy and safety of today’s widely used inhalation devices. The technology as we know it truly came into existence almost 60 years ago, when the pressurized metered dose inhaler (MDI) was invented. Today, these products are primarily used to treat COPD and asthma, but they are also suitable for many other therapeutic areas, including nasal drug delivery.

Related News

PHARMACY MARKET

PCI Pharma Services Announces the Closing of Its Acquisition of LSNE

PCI Pharma Services | December 15, 2021

PCI Pharma Services a leading global contract development and manufacturing organizatio announced the closing of the previously announced acquisition of Lyophilization Services of New England, Inc. a premier contract development and manufacturing organization headquartered in Bedford, New Hampshire. This acquisition is a key step for PCI, as LSNE will expand PCI’s breadth of services as a global CDMO, building on its expertise in specialty manufacturing, clinical trial supply and pharmaceutical packaging. PCI is now able to offer integrated large and small molecule solutions for its clinical and commercial clients, including global manufacturing capabilities in complex formulations, high potency, sterile fill-finish, and lyophilization, an important manufacturing process commonly used with injectable and biologic therapies. Founded in 1997, LSNE has an impressive history of serving global pharmaceutical, biotechnology and medical device companies. LSNE is differentiated by its high-quality cGMP aseptic fill-finish capabilities, and expertise in and ability to scale lyophilization. LSNE brings to PCI five FDA-approved facilities in the U.S. and Europe with a sixth expecting approval early in the new year. The closing of this acquisition, along with the capital commitments for significant capacity expansion and PCI’s recently announced construction of a New England Clinical Center of Excellence, will also help create a centralized hub for its Northeast clients. The injectable CDMO market is a high-growth segment outpacing the overall pharmaceutical outsourcing market and PCI is making significant investments, like this acquisition, to respond to the evolving industry landscape. This is PCI’s fourth acquisition in three years, reinforcing the company’s commitment to add new capabilities and scale to help its clients continue bringing life-changing therapies to patients all over the world. About PCI Pharma Services PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries and over 4,300 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients’ lives.

Read More

BUSINESS INSIGHTS

TriMas Announces Two New Acquisitions

TriMas | December 14, 2021

TriMas announced that it has recently signed agreements to acquire Omega Plastics to be added to TriMas Packaging, and TFI Aerospace to be added to TriMas Aerospace. Omega, located in Clinton Township, Michigan, specializes in manufacturing custom components and devices for drug delivery, diagnostic and orthopedic medical applications, as well as components for industrial applications. Omega leverages its advanced in-house tool making capabilities, ISO13485-certified injection molding facility and ISO Class 8 clean room to provide its customers a faster product development cycle, from prototype development, testing and validation, to short and medium run production and assembly. Omega is an approved vendor to several leading medical device companies, with a long track record of unparalleled service and quality. Omega currently operates as a private, family-owned company, and is expected to generate approximately $18 million in revenue in fiscal year 2021. “We are excited to announce the agreement between TriMas and Omega. We look forward to expanding Omega’s production capacity to benefit its customers’ longer-term needs, while also leveraging Omega’s advanced tool making capabilities to add rapid prototyping to enhance TriMas Packaging’s speed-to-market advantage on innovation and new product designs. The addition of Omega further expands our Pharmaceutical & Nutraceutical product offerings into additional medical applications, which we believe is an attractive market for long-term growth.” Thomas Amato, President and Chief Executive Officer of TriMas Located near Toronto, Canada, TFI is a leading manufacturer and supplier of specialty fasteners used in a variety of applications, predominantly for the aerospace end market. TFI currently operates as a private, family-owned company, and is expected to generate approximately $6 million in revenue in fiscal year 2021. “In addition to expanding TriMas Packaging through the acquisition of Omega, we are also pleased to announce the acquisition of TFI,” Amato continued. “This acquisition will further expand TriMas Aerospace’s fastener product lines with the addition of complimentary niche products that have an exciting growth trajectory resulting from TFI’s new program wins and the overall aerospace market recovery. We anticipate TFI’s customers will benefit from the added innovation and manufacturing depth offered by TriMas Aerospace, while TriMas Aerospace’s customers will enjoy additional product offerings.” Amato continued, “We continue to execute on our core strategy of augmenting our growth through bolt-on acquisitions by leveraging our strong cash generation. After closing these two acquisitions, we expect our net leverage ratio to remain below 2.0x, providing ample capacity to execute on additional bolt-on acquisitions while also returning capital to shareholders through dividends and share buybacks.” TriMas expects to close on Omega by the end of the year, and closed on TFI simultaneously with signing. “We look forward to welcoming both Omega and TFI to the TriMas family of businesses,” concluded Amato. About TriMas TriMas is a global manufacturer and provider of products for customers primarily in the consumer products, aerospace and industrial markets, with approximately 3,300 dedicated employees in 11 countries. We provide customers with a wide range of innovative and quality product solutions through our market-leading businesses. Our TriMas family of businesses has strong brand names in the markets served, and operates under a common set of values and strategic priorities under the TriMas Business Model. TriMas is publicly traded on the NASDAQ under the ticker symbol “TRS,” and is headquartered in Bloomfield Hills, Michigan.

Read More

CPD AND LEARNING

PostEra and NeuroLucent Partners on identifying small-molecule therapeutics for Alzheimer's disease

PostEra | November 27, 2020

PostEra, a biotechnology organization offering restorative science fueled by AI, today reported a joint effort with NeuroLucent, a Chicago-put together organization centered with respect to creating novel medicines for Alzheimer's sickness and different dementias. The disappointment of late-stage clinical preliminaries to reveal viable treatments for Alzheimer's illness has underscored the need to investigate novel helpful methodologies. NeuroLucent is creating novel little atom aggravates that standardize a key calcium direct that is dysregulated in Alzheimer's neurons and reestablish ordinary neuronal capacity in different preclinical Alzheimer's models. NeuroLucent has collaborated with PostEra to quicken its quest for a helpful up-and-comer. PostEra will utilize its AI innovation to upgrade NeuroLucent's lead mixes through a progression of 'plan make-test' cycles that has recently been appeared to quicken therapeutic science crusades. PostEra will likewise use its Manifold stage, which gives admittance to mixes through an overall organization of merchants and accomplice contract research associations. Business terms incorporate a forthright installment to PostEra, with extra installments upon the accomplishment of specific achievements. "We're excited about the potential of integrating PostEra's technology into the design of more potent compounds," said Bill Kohlbrenner, CEO of NeuroLucent. "We are intrigued by PostEra's machine learning algorithm since it doesn't require detailed structural information related to the drug target. We're looking forward to seeing what impact PostEra's AI solutions will have on our program." About NeuroLucent NeuroLucent holds an exclusive license to technology developed at the Rosalind Franklin University of Medicine and Science by Dr. Grace (Beth) Stutzmann, who uncovered a link between aberrant Ca2+ signalling, long known to occur in Alzheimer's neurons, and a Ca2+ channel that becomes 'leaky' in disease. NeuroLucent's preclinical stage compounds have been validated in multiple disease models and the current company focus is on identifying a clinical development candidate that addresses the cognitive loss associated with Alzheimer's disease.

Read More